The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30 C. and 40 C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30 C., and six months at 50 C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.

The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30 C. and 40 C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30 C., and six months at 50 C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.

Methods for preparing dried pellets of biological materials are described. The pellets can have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a solid surface followed by microwave vacuum drying the frozen droplets. These methods are useful for preparing dried pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.

Methods for preparing dried pellets of biological materials are described. The pellets can have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a solid surface followed by microwave vacuum drying the frozen droplets. These methods are useful for preparing dried pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.

Provided herein are diagnostics and vaccines to identify control and prevent novel porcine orthoreovirus type 3 (POV3) isolated from diarrheic feces of piglets from outbreaks in three states and ring-dried swine blood meal from multiple sources.

Provided herein are diagnostics and vaccines to identify control and prevent novel porcine orthoreovirus type 3 (POV3) isolated from diarrheic feces of piglets from outbreaks in three states and ring-dried swine blood meal from multiple sources.

An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial -helical domain, the hinge domain, the -triple spiral domain and a full or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said -helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial -helical domain, the hinge domain, the -triple spiral domain and a full or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said -helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

The present invention relates to immunogenic compositions comprising recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to an immunogenic composition containing (i) a fusion protein comprising in N- to C-terminal direction (A) an immunogenic fragment of a rotavirus VP8 protein and (B) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, and (ii) an immunogenic substance, different from said fusion protein, wherein said immunogenic composition is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.

The present invention relates to immunogenic compositions comprising recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to an immunogenic composition containing (i) a fusion protein comprising in N- to C-terminal direction (A) an immunogenic fragment of a rotavirus VP8 protein and (B) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, and (ii) an immunogenic substance, different from said fusion protein, wherein said immunogenic composition is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.